ArticleEndocrine2018

Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide.

D Bengtsson et al.PubMed ↗Publisher ↗

No numbers read from the abstract.